ArticleEuropean journal of obstetrics & gynecology and reproductive biology: X2026
Malignant transformation of endometriosis into endometrioid ovarian carcinoma with a contralateral borderline seromucinous tumour: A rare case report.
Article in European journal of obstetrics & gynecology and reproductive biology: X, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Endometriosis-associated ovarian cancer is uncommon and is most often represented by endometrioid and clear cell carcinomas. Synchronous contralateral borderline ovarian tumours are uncommon and may be missed when gross intraoperative assessment is reassuring. Case: A 43-year-old woman with a confirmed diagnosis of endometriosis for approximately 5 years presented with worsening pelvic pain and menstrual symptoms. A left ovarian endometrioma increased from 6.1 × 6.8 × 5.2 cm in April 2024 to 8.8 × 9 × 9.5 cm in April 2025, with subsequent MRI showing a complex mass with solid components (O-RADS MRI 5). CA-125 was 408.6 U/mL and CA 19-9 was 643.58 U/mL; RMI-I was 1225.8 (U = 3, M = 1, CA-125 = 408.6). Staging laparotomy was performed. Histopathology demonstrated grade 2 endometrioid adenocarcinoma arising in an endometriotic cyst of the left ovary, FIGO stage IC1, while the grossly normal-appearing right ovary contained a borderline seromucinous tumour with endometrioid differentiation. The omentum, peritoneal cytology, and all 31 sampled lymph nodes were negative for malignancy. Immunohistochemistry supported endometrioid carcinoma. Conclusion: This case highlights the importance of interval change and suspicious imaging features in an endometrioma, the limitations of gross intraoperative assessment of the contralateral ovary, and the value of complete histopathological examination in identifying synchronous bilateral ovarian pathology.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.